Trials / Not Yet Recruiting
Not Yet RecruitingNCT04701619
Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies (IMMUNOSTROKE)
Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild · Network
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
IMMUNOSTROKE study aims to describe the immuno-inflammatory and thrombo-inflammatory profiles during the course of AIC management by reperfusion treatment and to monitor changes in these different parameters over time. Post-hoc analyses will make it possible to correlate the immuno-inflammatory and thrombo-inflammatory profiles and their evolution with the clinical outcome in terms of post-AIC functional and cognitive disability.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Immuno-inflammatory profile description in patients with ischemic stroke | Patients will be evaluated for inflammatory biomarkers at inclusion, at 24-48 hours of reperfusion treatment , at 72 hours, at 7 days or at discharge if before D7, at discharge if after D7, at 3 months and at 1 year.The biomarkers will be measured using ELISA panels for inflammatory biomarkers |
Timeline
- Start date
- 2026-09-15
- Primary completion
- 2027-10-15
- Completion
- 2028-05-15
- First posted
- 2021-01-08
- Last updated
- 2026-01-20
Source: ClinicalTrials.gov record NCT04701619. Inclusion in this directory is not an endorsement.